Join
Live feed
·
PRReleasevia Quantisnow
Allakos Inc. logo

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

ByQuantisnow·Wall Street's wire, on your screen.
ALLK· Allakos Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLK (Allakos Inc.) and more on Quantisnow.